While we have heard a lot about brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant – SAGE 217 or zuranolone – has been [...]
As women transition into the menopause, they experience a constellation of symptoms including vasomotor symptoms (hot flashes and night sweats), sleep disruption, problems with sexual functioning, and cognitive impairment. Women may also be more [...]
Over the last decade, various studies have examined the risk of obstetric complications in women using antidepressants during pregnancy. Preeclampsia: Some studies have suggested that pregnant women taking SSRI antidepressants may be at higher [...]
While we have considerable data regarding the reproductive safety of antidepressants, including the selective serotonin reuptake inhibitors (SSRIs), most studies have focused on the prevalence of major malformations in children with prenatal exposure to [...]
While we have been talking about using brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant - SAGE 217 or zuranolone - has [...]
A recent study looks at the risk for gestational diabetes in women taking antidepressants during pregnancy. In this study from Quebec, women with gestational diabetes mellitus (GDM) diagnosed after the 20th week of pregnancy [...]
For women with histories of major depression, choosing whether to maintain or to discontinue treatment with an antidepressant during pregnancy is often challenging. This is a process which requires careful and thoughtful consideration, weighing the [...]
Concerns regarding a link between antidepressant use during pregnancy and autism emerged when two epidemiologic studies demonstrated an association between prenatal exposure to selective serotonin reuptake inhibitor antidepressants (SSRIs) with an increased risk of autism [...]
The following post was first published in OB/GYN News. Please see our OB/GYN News archives here. Publish date: November 1, 2016 By: Gerald G. Briggs, BPharm, FCCP, Christina Chambers, PhD, MPH, Lee S. Cohen, MD, & Gideon Koren, MD Editor’s note: As [...]
An updated version of this post can be found HERE. Two thirds of all breast cancer tumors are known to have receptors that respond to hormones; that is they can grow in response to estrogen. [...]
